Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $17.1667.

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Citizens Jmp decreased their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Finally, Barclays assumed coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target on the stock.

Altimmune Price Performance

Shares of ALT opened at $4.65 on Wednesday. The company has a 50 day moving average of $4.66 and a two-hundred day moving average of $4.20. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73. The company has a market cap of $524.66 million, a price-to-earnings ratio of -4.35 and a beta of 0.09.

Insider Buying and Selling at Altimmune

In other news, Director John Gill purchased 12,500 shares of the company’s stock in a transaction on Tuesday, December 23rd. The shares were acquired at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the purchase, the director owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerome Benedict Durso acquired 12,500 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 30,527 shares of company stock worth $125,278. 4.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Altimmune

Several hedge funds have recently added to or reduced their stakes in ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Altimmune in the first quarter worth about $50,000. Concurrent Investment Advisors LLC boosted its stake in shares of Altimmune by 16.4% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 25,258 shares of the company’s stock worth $98,000 after acquiring an additional 3,565 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Altimmune by 25,474.2% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 239,630 shares of the company’s stock valued at $927,000 after acquiring an additional 238,693 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Altimmune by 48.0% during the second quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock worth $127,000 after purchasing an additional 10,671 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.